Abstract:Authors' reply Sir—We disagree with C J Hawkey and colleagues that elderly patients with comorbid conditions do not warrant prophylactic treatment. These patients are at increased risk of developing gastrointestinal complications induced by the use of non-steroidal anti-inflammatory drugs (NSAIDs).1Silverstein FE Graham DY Senior JR et al.Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomised, double-blind, placebo-controlled trial.Ann Intern Med. 1995; 123: 241-249Crossref PubMed Scopus (1108) Google Scholar Moreover, patients without previous exposure to NSAIDs are also at risk, particularly during the first few weeks of NSAID therapy.2Langman MJS Weil J Wainwright P et al.Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.Lancet. 1994; 343: 1075-1078Summary PubMed Scopus (843) Google Scholar Although little could be done for this group of patients in the past, our proposal to eradicate Helicobacter pylori in these patients is a quick and cheap primary preventive treatment, unlike the long-term use of acid-suppression drugs. Certainly, the issue of interaction between H pylori and NSAIDs in the pathogenesis of peptic ulcers is far from settled. Hawkey and co-workers make the interesting observation that acid-suppressive-maintenance treatment is more effective in individuals infected with H pylori than in those not infected. However, the primary aim of their study was to compare the protective effects of two acid-suppressive agents against NSAID-induced injury, instead of the role of H pylori infection. Furthermore, the same group of investigators have also reported a synergistic effect between H pylori and aspirin in the development of bleeding peptic ulcers.3Hawkey GM Stack WA Pearson G Everitt S Logan RFA Hawkey CJ Nonsteroidal anti-inflammatory drugs, aspirin and Helicobacter pylori as risk factors for bleeding ulcers.Gut. 1997; 29: A5Google Scholar We suspect that the interaction between H pylori and NSAIDs may not be a simple all-or-none relation. Such factors as history of ulcer disease, gastric or duodenal ulcer, and bleeding or non-bleeding ulcers may all affect the outcome of the patients. A simple 1-week course of antimicrobial therapy would be a pragmatic and cost-effective way to reduce the risk of gastrointestinal complications. O M P Jolobe notes the confounding effect of spontaneous healing, but spontaneous ulcer healing with long-term NSAID therapy would have had little influence on the outcome of our study because of the large difference in the rate of peptic ulcers between H pylori-positive (26%) and H pylori-negative (3%) patients. The rate of ulcers in the H pylori-positive group agreed with that reported by Ekstrom and colleagues'4Ekstrom P Carling L Wetterhus S et al.Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multicentre study.Scand J Gastroenterol. 1996; 31: 753-758Crossref PubMed Scopus (256) Google Scholar long-term study, which showed that the lesions observed were not simply a transient response to acute mucosal injury. Most of our patients were older than 60 years and, thus, were more susceptible to NSAID-related injury. The age distribution may also explain why studies based on young, healthy volunteers do not show any positive interaction between use of NSAIDs and H pylori.5Thillainayagam AV Tabaqchali S Warrington SJ Farthing MJG Interrelationships between Helicobacter pylori infection, non-steroidal anti-inflammatory drugs and gastroduodenal disease: a prospective study in healthy volunteers.Dig Dis Sci. 1994; 39: 1085-1089Crossref PubMed Scopus (61) Google Scholar However, since the mean age of our two treatment groups were similar, age-related risk cannot account for the remarkable between-group difference in the rate of gastric and duodenal ulcers. Helicobacter pylori, NSAIDs, and peptic ulcersFrancis Chan and colleagues (Oct 4, p 975)1 suggest that eradication of Helicobacter pylori may prevent peptic ulcers caused by the use of nonsteroidal anti-inflammatory drugs (NSAIDs). The patients Chan and co-workers investigated would not usually be considered for preventative treatment since they were excluded from the study if they had had previous exposure to NSAIDs, a history of peptic ulcer disease, or an ulcer at the baseline endoscopy. These exclusion criteria may explain why individuals who did not have H pylori did so well in the study compared with previous studies in which H pylori has had little or no effect on the risk of developing ulcers or ulcer complications. Full-Text PDF Helicobacter pylori, NSAIDs, and peptic ulcersIn the study by Francis Chan and colleagues,1 the 8 weeks' duration of naproxen therapy may have been too short to allow for the confounding effect of spontaneous healing, as reported by Davis and co-workers2 in six of 13 patients who continued to take non-steroidal anti-inflammatory drugs (NSAIDs) in the placebo group of a trial evaluating cimetidine over a 6-week period. Another important confounding variable is the age-related nature of susceptibility to NSAID-related gastropathy3—probably due to the age-related decline in gastroduodenal prostaglandin content. Full-Text PDF

Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial

Does Eradication of Helicobacter Pylori Impair Healing of Nonsteroidal Anti-Inflammatory Drug Associated Bleeding Peptic Ulcers? A Prospective Randomized Study.

Should We Eradicate Helicobacter Pylori Infection in Patients Receiving Nonsteroidal Anti-Inflammatory Drugs or Low-Dose Aspirin?

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Effect of Drug Treatment on Hyperplastic Gastric Polyps Infected with Helicobacter Pylori: A Randomized, Controlled Trial

Helicobacter Pylori, NSAIDs, and Peptic Ulcers

Helicobacter Pylori Infection and Nonsteroidal Anti-inflammatory Drug Use: Eradication, Acid-Reducing Therapy, or Both?

Prospective Randomized Trial of H-Pylori Eradication Versus Maintenance Omeprazole to Prevent Recurrent Upper Gastrointestinal Hemorrhage in High-Risk Aspirin and Non-Aspirin Nsaid Users.

Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis.

Helicobacter Pylori and Nonsteroidal Anti-Inflammatory Drugs

Preventing Recurrent Upper Gastrointestinal Bleeding in Patients with Helicobacter Pylori Infection Who Are Taking Low-Dose Aspirin or Naproxen

Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users.

Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment

Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.

Interaction of Helicobacter Pylori Infection and Low-Dose Aspirin in the Upper Gastrointestinal Tract: Implications for Clinical Practice

Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial

Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors

Management of High-risk Patients on Non-steroidal Anti-inflammatory Drugs or Aspirin

Therapeutic Management of Recurrent Peptic Ulcer Disease

Similar Efficacy of Proton-Pump Inhibitors Vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.